Weekly Recap | LABU.US +0.73%, biotech ends mixed
I'm LongbridgeAI, I can summarize articles.LABU.US rose 0.73% this week to close at $263.20, outperforming the S&P 500’s 0.08% dip by roughly 0.81 percentage points. The week was choppy with a 14.21% amplitude: it opened at $264.98 on Monday, slid to $242.96 on Tuesday, spiked to $280.62 on Thursday, then faded to finish Friday at $263.20, nearly back to the prior week’s close.
The Week
LABU.US rose 0.73% this week to close at $263.20, outperforming the S&P 500’s 0.08% dip by roughly 0.81 percentage points. The week was choppy with a 14.21% amplitude: it opened at $264.98 on Monday, slid to $242.96 on Tuesday, spiked to $280.62 on Thursday, then faded to finish Friday at $263.20, nearly back to the prior week’s close.
Key Events
The biotech tape was driven by individual stories rather than a single sector-wide move. Moderna (MRNA) was the standout, with Phase III melanoma data and its vaccine pipeline in focus; some call options on MRNA jumped 381% on Thursday. Twist Bioscience gained attention after its AI drug-discovery tie-up with Lilly’s TuneLab, though BWS Financial reiterated a sell rating with a $45 target. Halozyme Therapeutics (HALO) upsized its convertible offering to $1.3 billion and hit a 12-month high. Natera released lung cancer MRD study results linking Signatera to three-year recurrence-free survival across 1,129 patients. The sector finished mixed, with no clear leader.
The Week Ahead
The macro calendar picks up on Thursday 24 September, with initial jobless claims, the current account balance, and new home sales all due. New home sales are expected at 0.608 million, barely above the prior 0.607 million. Earlier in the week, the Richmond Fed composite index lands on Tuesday and EIA crude and Cushing inventories on Wednesday. On the biotech side, follow-through on this week’s single-name catalysts, particularly Moderna and Twist Bioscience, will be worth monitoring.
In Short
LABU.US closed higher but with unusually wide intraweek swings, as buyers and sellers rotated quickly between Monday and Thursday. The biotech sector produced plenty of company-specific news, yet the index lacked sustained direction, and the broader S&P 500 finished marginally lower. On the latest trading day, retail-sized flows were relatively more active on the buy side, while large-lot flow showed little clear direction. The question ahead is whether these single-stock catalysts broaden into a sector-wide move, and how the week’s macro data shapes risk appetite.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.